The company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...

Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. The acquisition ...

Boehringer Ingelheim halts Iclepertin trials after failure to show efficacy Boehringer Ingelheim stops research on Iclepertin ...

Boehringer Ingelheim announced that its schizophrenia drug, iclepertin, did not achieve statistically significant ...

Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...

Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...

today announced its collaboration with Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) at the 2025 Tournament of Roses® Parade. The partners have joined forces to share a powerful ...

Guardant Health (GH) announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360 CDx liquid biopsy as a companion diagnostic for ...